Mitochondrial disease with dilated cardiomyopathy

Mitochondrial disease with dilated cardiomyopathy (Orphanet code 217613) refers to a group of rare genetic disorders in which dysfunction of the mitochondria — the energy-producing structures within cells — leads to dilated cardiomyopathy (DCM), a condition where the heart's left ventricle becomes enlarged and weakened, impairing its ability to pump blood effectively. Because the heart is a highly energy-dependent organ, it is particularly vulnerable to defects in mitochondrial energy metabolism. These disorders can result from mutations in either mitochondrial DNA (mtDNA) or nuclear genes that encode mitochondrial proteins essential for oxidative phosphorylation and other metabolic pathways. Clinical features primarily involve the cardiovascular system, with progressive heart failure, reduced cardiac contractility, and arrhythmias being hallmark manifestations. However, because mitochondrial dysfunction affects multiple organ systems, patients may also present with skeletal myopathy, neurological symptoms (such as developmental delay, seizures, or stroke-like episodes), lactic acidosis, growth failure, and multi-organ involvement including the liver, kidneys, and endocrine system. The severity and age of onset can vary widely, ranging from severe neonatal or infantile presentations with rapidly progressive heart failure to later-onset forms with a more gradual clinical course. Treatment is largely supportive and symptomatic. Management of heart failure follows standard cardiological protocols, including the use of ACE inhibitors, beta-blockers, diuretics, and in severe cases, consideration of cardiac transplantation. Supplementation with cofactors such as coenzyme Q10, riboflavin, L-carnitine, and thiamine may be trialed, though evidence for their efficacy remains limited. Avoidance of metabolic stressors such as fasting, illness, and certain medications is important. Genetic counseling is essential given the variable inheritance patterns associated with these conditions. No curative therapy currently exists, and prognosis depends on the specific genetic defect, severity of cardiac involvement, and extent of multi-organ disease.

Common questions about Mitochondrial disease with dilated cardiomyopathy